Arrhythmias & electrophysiology
Risk of serious hypoglycaemia in patients with atrial fibrillation and diabetes concurrently taking antidiabetic drugs and oral anticoagulants: a nationwide cohort study
Main finding · Serious hypoglycaemiaResult — go to the resultIncidence rate ratio 0.73 95% CI 0.63–0.85Authors' conclusion
In patients with AF and DM taking antidiabetic drugs, concurrent use of NOACs was associated with a lower risk of serious hypoglycaemia than concurrent use of warfarin.
Study context
- Population
- Adults with atrial fibrillation (AF) and diabetes mellitus (DM) taking antidiabetic drugs and OAC, Taiwan National Health Insurance Research Database, 2012–2020
- Participants
- 56,774 adults
- Exposure
- Antidiabetic drugs with NOACs vs with warfarin
- Outcome
- Serious hypoglycaemia
Methodological detailsnationwide, stabilized inverse probability of treatment weighting
- Nationwide
- Stabilized inverse probability of treatment weighting
Main finding
As reported in the abstract
Incidence rate ratio
0.73
95% CI 0.63–0.85
P < 0.001
NOACsvs Warfarin
IRR 0.73 (95% CI 0.63–0.85); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | IRR (95% CI) | P value | |
|---|---|---|---|
| Serious hypoglycaemia, by individual NOACDabigatranvs Warfarin | 0.76 (0.63–0.91) | P = 0.002 | |
| Serious hypoglycaemia, by individual NOACRivaroxabanvs Warfarin | 0.72 (0.61–0.86) | P < 0.001 | |
| Serious hypoglycaemia, by individual NOACApixabanvs Warfarin | 0.71 (0.57–0.89) | P = 0.003 | |
| 0.512Incidence rate ratio (log scale) |
Original publication
Risk of serious hypoglycaemia in patients with atrial fibrillation and diabetes concurrently taking antidiabetic drugs and oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. Published 22 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →